医学信息Issue(22)：84-85,2.
埃克替尼治疗化疗失败的晚期非小细胞肺癌临床评价
Clinical Value in Treatment with Icotinib in Advanced Non-small Cell Lung Cancer Patients Failed to Previous Chemotherapy
何清 1冯仲珉 1孙鹏 1刘丽丽 1于佩瑶 2刘基巍 2张阳2
作者信息
- 1. 大连医科大学附属第二医院肿瘤科，辽宁 大连 116031
- 2. 大连医科大学附属第一医院肿瘤科，辽宁 大连 116011
- 折叠
摘要
Abstract
Objective To observe the ef icacy, safety in treatment with icotinib in advanced non-smal celllung cancer (NSCLC) patients failed to previous chemotherapy. Methods:25 patients treated with icotinib 125 mg,po,twice a day until progression or unacceptable toxicity. Results:The objective response rate was 28%and the disease control rate was 80%. Median Time to Progress was 5.1months. The main toxicity were skin rash and elevated aminotransferase. Conclusions:Icotinib is an ef ective in the treatmean of advanced non-smal celllung cancer . Al of patients are wel-tolerated.关键词
非小细胞肺癌/埃克替尼/近期疗效/安全性Key words
Non-smal celllung cancer (NSCLC)/Icotinib/Short-term effect/Safety引用本文复制引用
何清,冯仲珉,孙鹏,刘丽丽,于佩瑶,刘基巍,张阳..埃克替尼治疗化疗失败的晚期非小细胞肺癌临床评价[J].医学信息,2013,(22):84-85,2.
